JP2000507939A5 - - Google Patents

Download PDF

Info

Publication number
JP2000507939A5
JP2000507939A5 JP1997533791A JP53379197A JP2000507939A5 JP 2000507939 A5 JP2000507939 A5 JP 2000507939A5 JP 1997533791 A JP1997533791 A JP 1997533791A JP 53379197 A JP53379197 A JP 53379197A JP 2000507939 A5 JP2000507939 A5 JP 2000507939A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997533791A
Other languages
English (en)
Other versions
JP2000507939A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/005071 external-priority patent/WO1997034618A1/en
Publication of JP2000507939A publication Critical patent/JP2000507939A/ja
Publication of JP2000507939A5 publication Critical patent/JP2000507939A5/ja
Withdrawn legal-status Critical Current

Links

Description

Figure 2000507939
Figure 2000507939
Figure 2000507939
Figure 2000507939
JP9533791A 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与 Withdrawn JP2000507939A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US08/620,444 1996-03-22
PCT/US1997/005071 WO1997034618A1 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma

Publications (2)

Publication Number Publication Date
JP2000507939A JP2000507939A (ja) 2000-06-27
JP2000507939A5 true JP2000507939A5 (ja) 2004-12-02

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9533791A Withdrawn JP2000507939A (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与
JP53358397A Expired - Fee Related JP4847634B2 (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP53358397A Expired - Fee Related JP4847634B2 (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法

Country Status (11)

Country Link
US (4) US6214796B1 (ja)
EP (3) EP1364655B1 (ja)
JP (2) JP2000507939A (ja)
KR (1) KR20000064752A (ja)
CN (1) CN1181885C (ja)
AT (2) ATE244574T1 (ja)
AU (2) AU725341B2 (ja)
CA (2) CA2249368A1 (ja)
DE (2) DE69740089D1 (ja)
ES (1) ES2201287T5 (ja)
WO (2) WO1997034626A1 (ja)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
KR100227406B1 (ko) 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
DE69826854T2 (de) 1997-05-05 2006-02-02 Curis, Inc., Cambridge Therapien zur behandlung von akutem nierenversagen
EP0985149A1 (en) * 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU6790300A (en) * 1999-08-18 2001-03-13 Children's Medical Center Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US20020119923A1 (en) 2000-06-01 2002-08-29 Benowitz Larry I. Methods and compositions for producing a neurosalutary effect in a subject
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
JP2004528042A (ja) * 2001-06-01 2004-09-16 エクサイト セラピーズ， インコーポレイテッド Ｔ細胞誘導性組織修復および再生
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
WO2004104185A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US20080108547A1 (en) * 2004-07-20 2008-05-08 Taylor Ii Larry Edmund Protease Inhibitor
JPWO2006011600A1 (ja) * 2004-07-29 2008-05-01 アンジェスＭｇ株式会社 脳機能改善のための医薬および方法
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
ES2534672T3 (es) 2005-11-12 2015-04-27 The Board Of Trustees Of The Leland Métodos relacionados con FGF2 para diagnosticar y tratar la depresión
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
SI2121142T1 (sl) * 2007-01-25 2012-12-31 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uporaba GDF-5 za izboljšanje ali vzdrževanje videza kože
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
EP2276458A1 (en) * 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
CA2752160A1 (en) * 2009-02-12 2010-08-19 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf-.beta. superfamily members
US20100204123A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
US8828937B2 (en) 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
EP2352750B1 (en) 2009-09-17 2012-06-13 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
CN102822197A (zh) 2009-12-22 2012-12-12 史赛克公司 具有降低的免疫原性的bmp-7变体
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
MX2013001977A (es) 2010-08-20 2013-04-03 Wyeth Llc Proteinas osteogenicas de diseño.
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2701727B1 (en) * 2011-03-04 2019-05-08 The Regents of The University of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
EP2734220A4 (en) * 2011-07-19 2015-01-21 Thrasos Innovation Inc ANTIFIBROTIC PEPTIDES AND THEIR USE IN METHODS OF TREATING FIBROSIS-CHARACTERIZED DISEASES AND SUFFERING
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
PT2981822T (pt) 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN116115629A (zh) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 核酸产品及其施用方法
WO2020010180A1 (en) * 2018-07-03 2020-01-09 Cardio Vascular Bio Therapeutics, Inc. Compositions and methods for treating stroke
EP4154001A4 (en) * 2020-05-19 2024-06-05 Elevian, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
EP0423206A1 (en) 1988-07-08 1991-04-24 University College London Analysis of cell modifying substances
WO1990000900A1 (en) 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
CA2042577A1 (en) 1989-10-17 1991-04-18 Hermann Oppermann Osteogenic devices
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
CA2085134C (en) 1990-06-15 2003-03-18 Carnegie Institution Of Washington Gdf-1
DE69133338T2 (de) 1990-09-26 2004-04-15 Genetics Institute, LLC, Cambridge Bmp-5-derivate
CA2094027C (en) 1990-10-18 2001-12-25 Hermann Oppermann Osteogenic peptides
JPH06505965A (ja) 1990-11-16 1994-07-07 セルトリックス　ファーマシューティカルズ，インコーポレイテッド β型トランスフォーミング成長因子
DE69132918T2 (de) 1990-11-27 2002-10-31 American National Red Cross, Washington Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
JP3356775B2 (ja) 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
DK0575555T3 (da) * 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
AU663328B2 (en) 1991-06-21 1995-10-05 Genetics Institute, Llc Pharmaceutical formulations of osteogenic proteins
DK0592562T3 (da) 1991-06-25 1999-08-30 Genetics Inst BMP-9-præparater
EP0601129B1 (en) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Morphogenic protein screening method
WO1993004692A1 (en) 1991-08-30 1993-03-18 Creative Biomolecules, Inc. Morphogen-induced modulation of inflammatory response
CA2116559C (en) 1991-08-30 2005-05-10 Thangavel Kuberasampath Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
EP0625050B1 (en) * 1991-11-22 1999-04-14 Genentech, Inc. Tgf-beta to improve neural outcome
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
AU681594B2 (en) * 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
JPH09501932A (ja) † 1993-08-26 1997-02-25 ジェネティックス・インスティテュート・インコーポレイテッド ヒト・骨形態形成蛋白を用いる神経再生
AU7605394A (en) 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues

Similar Documents

Publication Publication Date Title
JP2000508561A5 (ja)
JP2000502280A5 (ja)
JP2000501771A5 (ja)
JP2000500076A5 (ja)
JP2000500055A5 (ja)
JP2000500026A5 (ja)
JP2001502086A5 (ja)
JP2000502472A5 (ja)
JP2000501825A5 (ja)
JP2000507939A5 (ja)
JP2000502485A5 (ja)
JP2000517074A5 (ja)
JP2000502425A5 (ja)
JP2000501774A5 (ja)
JP2000502570A5 (ja)
JP2000502568A5 (ja)
JP2000501876A5 (ja)
JP2000501744A5 (ja)
JP2000509412A5 (ja)
JP2000502316A5 (ja)
JP2000502714A5 (ja)
JP2000500318A5 (ja)
JP2000502479A5 (ja)
JP2000500184A5 (ja)
JP2000500662A5 (ja)